Cargando…
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project
BACKGROUND: Incorporating real‐world data in the drug development process allows the improvement of health outcomes by providing better representation of actual patterns of drug safety and efficacy. AIMS AND METHODS: Here, we present the results of a retroprospective, observational real‐life study o...
Autores principales: | Coltro, Giacomo, Sant'Antonio, Emanuela, Palumbo, Giuseppe A., Mannelli, Francesco, De Stefano, Valerio, Ruggeri, Marco, Elli, Elena M., Zanotti, Roberta, Borsani, Oscar, Bertozzi, Irene, Duminuco, Andrea, Betti, Silvia, Carli, Giuseppe, Cavalca, Fabrizio, Tanasi, Ilaria, Rumi, Elisa, Randi, Maria L., Garibaldi, Bruno, Loscocco, Giuseppe G., Guglielmelli, Paola, Vannucchi, Alessandro M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134270/ https://www.ncbi.nlm.nih.gov/pubmed/36708083 http://dx.doi.org/10.1002/cam4.5618 |
Ejemplares similares
-
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
por: Breccia, Massimo, et al.
Publicado: (2019) -
Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance
por: Breccia, Massimo, et al.
Publicado: (2022) -
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
por: Coltro, Giacomo, et al.
Publicado: (2022) -
Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
por: Loscocco, Giuseppe G., et al.
Publicado: (2021) -
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)